The effects and efficacy of Zanubrutinib

Zanubrutinib is effective in slowing the progression of Waldenströ's macroglobulinemia in both previously untreated patients and in patients whose cancer has not responded to previous treatments. Zanubrutinib has also been shown to be effective in the treatment of marginal zone lymphoma that has relapsed or failed to respond to at least one prior therapy targeting CD20. In addition, zanubrutinib has been shown to be effective in treating chronic lymphocytic leukemia (CLL) when the disease has not been previously treated, or when it has relapsed or failed to respond to at least one previous treatment. The side effects of zanubrutinib are considered manageable.

Zanubrutinib is a novelBruton tyrosine kinase (BTK) inhibitor indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcome, and long-term survival. BTK is an enzyme that functions in oncogenic signaling pathways, promoting the survival and proliferation of malignant B cells. Compared with ibrutinib, the first-generation BTK inhibitor, zanubrutinib exhibits higher potency and selectivity against BTK and fewer off-target effects. Due to its enhanced selectivity for BTK, zanubrutinib belongs to the second-generation BTK inhibitor drug group.

The original drug of zanubrutinib has been launched in China and has been included in the medical insurance. The price of 80mg*64 capsules per box may be around 6,000 yuan. The original drug of zanubrutinib marketed overseas is relatively expensive. There are currently no generic drugs of zanubrutinib on the market.